Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ...

SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq ... safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously.

(RTTNews) - Silo Pharma, Inc. (SILO) on Tuesday announced positive early findings from its ongoing study evaluating the pharmacokinetics, safety, and tolerability of SP-26, a novel ketamine-based ...

Silo Pharma, Inc. announced encouraging preliminary results from an ongoing study of its SP-26 ketamine extended-release rods, which are being evaluated for safety and pharmacokinetics after being ...

If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval. About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage ...

SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO ... safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

The yearslong bankruptcy case could be coming to a close. Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid ...

SARASOTA, FL - Silo Pharma , Inc. (NASDAQ:SILO), a $6.91 million market cap biopharmaceutical company currently trading at $1.54 per share, has announced promising preliminary results from a study on ...